OSLO, Norway, June 01, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
OSLO, Norway, May 30, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Nykode Therapeutics announces positive final results from its Phase 2 trial of VB10.16 in combination with PD-L1 inhibitor atezolizumab in advanced cervical cancer
Nykode Therapeutics to announce financial results for the fourth quarter 2022 and host webcast presentation on February 28, 2023
Nykode Therapeutics Announces Collaboration with The GOG Foundation, Inc. to Conduct the VB-C-04 Trial in Advanced Cervical Cancer
Nykode Therapeutics to Present at SVB Securities Global Biopharma Conference
Nykode Therapeutics, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, has entered into a manufacturing partnership with Richter-Helm BioLogics to supply plasmid DNA for Nykode’s wholly owned and partnered product portfolio.
OSLO, Norway, Dec. 23, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Nykode announces expanded clinical development plan for its lead cancer vaccine VB10.16 in HPV16-positive cancers
Nykode Therapeutics and Richter-Helm BioLogics Announce Strategic Manufacturing Partnership